抗癌化疗诱导的动脉硬性心血管疾病:综合性审查
Juan S Izquierdo-Condoy1, Marlon Arias-Intriago1, Diego Alexander Becerra Cardona2
1One Health Research Group, Universidad de las Américas, Quito 170124, Ecuador.
Life (Basel, Switzerland)
|February 26, 2025
概括
在癌症幸存者中,抗癌疗法增加了心血管风险,特别是动脉样硬化心血管疾病 (ASCVD). 早期风险评估和管理策略对于改善结果至关重要.
科学领域:
- 心脏瘤学 - 心脏瘤学
- 在瘤学瘤学.
- 心血管医学 心血管医学
背景情况:
- 抗癌药物显著改善癌症存活率,但引入心血管风险.
- 动脉样性心血管疾病 (ASCVD) 是癌症幸存者的发病和死亡的主要原因.
- 多因素机制,包括内皮功能障碍和炎症,在这个人群中推动ASCVD的发展.
研究的目的:
- 审查抗癌化疗有助于ASCVD的机制.
- 要突出评估和管理化学疗法诱导的ASCVD的策略.
- 讨论不同类型的抗癌剂所带来的独特心血管挑战.
主要方法:
- 关于抗癌药物及其心血管作用的文献综述.
- 检查包括氧化应激,炎症和脂质代谢障碍在内的机制.
- 分析风险评估工具和管理策略,包括药理和生活方式干预措施.
主要成果:
- 不同的化疗类别 (例如,人环素,税,VEGF抑制剂) 通过特定的途径诱导ASCVD.
- 在治疗前进行风险评估,确定传统和癌症特异性因素至关重要.
- 建议采取涉及风险分层,他类药物,ACE抑制剂和生活方式改变的多学科管理.
结论:
- 化疗诱导的ASCVD需要一个全面的,多学科的方法来有效地缓解.
- 心血管瘤病房和长期监测改善了护理协调和早期干预.
- 积极的心血管风险管理可以提高癌症患者的生存率和结果.
相关概念视频
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
Ischemic Heart Disease: Overview
1.1K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
455
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
455
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
437
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
437
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K


